Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0162871 (
abdominal aortic aneurysm
)
8,664
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Prospective studies evaluating risk factors for
abdominal aortic aneurysm
are few. We studied the association of life-style factors with risk for
abdominal aortic aneurysm
among 29,133 male smokers 50-69 years of age, participants in the Alpha-
Tocopherol
, Beta-Carotene Cancer Prevention Study. During a mean follow-up of 5.8 years, 181 were diagnosed with ruptured
abdominal aortic aneurysm
or nonruptured
abdominal aortic aneurysm
plus aneurysmectomy. Risk for
abdominal aortic aneurysm
was positively associated with age [relative risk (RR) = 4.56, 95% confidence interval (CI) = 2.42-8.61 for > 65 vs < or = 55 years], smoking years (RR = 2.25, 95% CI = 1.33-3.81 for > 40 vs < or = 32 years), systolic blood pressure (RR = 1.92, 95% CI = 1.13-3.25 for > 160 vs < or = 130 mmHg), diastolic blood pressure (RR = 1.80, 95% CI = 1.05-3.08 for > 100 vs < or = 85 mmHg), and serum total cholesterol (RR = 1.85, 95% CI = 1.09-3.12 for > 6.5 vs < or = 5.0 mmol/liter). High-density lipoprotein cholesterol showed a strong inverse association with risk for aortic aneurysm (RR = 0.16, 95% CI = 0.08-0.32 for > 1.5 vs < or = 0.9 mmol/liter). High energy intake was associated with lower risk for aortic aneurysm (RR = 0.59, 95% CI = 0.38-0.94 for the highest quartile vs the lowest), whereas no associations with nutrients were evident. We conclude that classical risk factors for atherosclerotic diseases seem to be important in pathogenesis of large abdominal aortic aneurysms.
...
PMID:Life-style factors and risk for abdominal aortic aneurysm in a cohort of Finnish male smokers. 1167 8
Multiple medical therapies have been proposed to prevent
abdominal aortic aneurysm
expansion. Use of these medications, hormones, vitamins, and dietary products is based on their ability to alter the pathophysiology of continued aortic wall growth. In this review, the explanation of how these medications can achieve suppression of
abdominal aortic aneurysm
is explained in relation to their effect on the various aspects of aortic wall inflammation. Despite the large number of animal and observational studies, there remain very few randomized clinical trials to support use of any of these agents. However, there may be sufficient evidence to suggest that statins, doxycycline,
vitamin E
, cyclooxygenase-2 inhibitors, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers can prove beneficial in some individuals.
...
PMID:Can pharmacologic agents slow abdominal aortic aneurysm growth? 2259 78